{"id":"propranolol-norfloxacin-vsl-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue / asthenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Propranolol reduces portal pressure and variceal bleeding risk via non-selective beta-blockade. Norfloxacin provides selective intestinal decontamination to reduce pathogenic gram-negative bacteria that contribute to bacterial translocation and hepatic encephalopathy. VSL#3 restores beneficial commensal bacteria to improve intestinal barrier function and reduce endotoxemia in cirrhotic patients.","oneSentence":"This is a combination therapy using propranolol (beta-blocker), norfloxacin (fluoroquinolone antibiotic), and VSL#3 (probiotic) to manage portal hypertension and associated complications through hemodynamic reduction, bacterial overgrowth suppression, and gut microbiota restoration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:35.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Portal hypertension and variceal bleeding prevention in cirrhosis"},{"name":"Hepatic encephalopathy prophylaxis in advanced liver disease"}]},"trialDetails":[{"nctId":"NCT01134692","phase":"PHASE3","title":"Probiotics for Portal Hypertension","status":"UNKNOWN","sponsor":"Govind Ballabh Pant Hospital","startDate":"","conditions":"Cirrhosis, Varices, Esophageal","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Propranolol, Norfloxacin, VSL#3","genericName":"Propranolol, Norfloxacin, VSL#3","companyName":"Govind Ballabh Pant Hospital","companyId":"govind-ballabh-pant-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy using propranolol (beta-blocker), norfloxacin (fluoroquinolone antibiotic), and VSL#3 (probiotic) to manage portal hypertension and associated complications through hemodynamic reduction, bacterial overgrowth suppression, and gut microbiota restoration. Used for Portal hypertension and variceal bleeding prevention in cirrhosis, Hepatic encephalopathy prophylaxis in advanced liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}